Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Mustang Bio Inc.
DescriptionEngineered chimeric antigen receptor (CAR) T cells targeting interleukin-13 (IL-13) receptor alpha 2 (IL-13RA2) (IL-13R) (CD213A2)
Molecular Target Interleukin-13 (IL-13) receptor alpha 2 (IL-13RA2) (IL-13R) (CD213A2)
Mechanism of Action 
Therapeutic ModalityCell therapy: Non-stem cell
Latest Stage of DevelopmentPhase I
Standard IndicationBrain cancer
Indication DetailsTreat IL-13RA2-positive recurrent or refractory malignant glioma
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today